Loading...

Nuvalent, Inc.

NUVLNASDAQ
Healthcare
Biotechnology
$76.80
$0.00(0.00%)

Nuvalent, Inc. (NUVL) Financial Performance & Income Statement Overview

View comprehensive annual and quarterly summaries for Nuvalent, Inc. (NUVL), featuring income statements, balance sheets, and cash flow data.

Revenue Growth
0.00%
Operating Income Growth
-87.55%
87.55%
Net Income Growth
-106.59%
106.59%
Operating Cash Flow Growth
-85.55%
85.55%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-33.16%
33.16%
ROIC
-37.50%
37.50%

Nuvalent, Inc. (NUVL) Income Statement & Financial Overview

View the income breakdown for Nuvalent, Inc. NUVL across both annual and quarterly reports.

MetricQ1 2025Q4 2024Q3 2024Q2 2024
Revenue$0.00$0.00$0.00$0.00
Cost of Revenue$0.00$0.00$0.00$0.00
Gross Profit$0.00$0.00$0.00$0.00
Gross Profit Ratio$0.00$0.00$0.00$0.00
R&D Expenses$74.42M$69.42M$60.55M$49.17M
SG&A Expenses$20.39M$16.88M$15.78M$15.98M
Operating Expenses$94.81M$86.30M$76.33M$65.15M
Total Costs & Expenses$94.81M$86.30M$76.33M$65.15M
Interest Income$11.82M$13.05M$8.63M$8.15M
Interest Expense$11.82M$0.00$0.00$0.00
Depreciation & Amortization$0.00-$52.59M$0.00$0.00
EBITDA-$94.81M-$86.30M-$76.33M-$65.15M
EBITDA Ratio$0.00$0.00$0.00$0.00
Operating Income-$94.81M-$86.30M-$76.33M-$65.15M
Operating Income Ratio$0.00$0.00$0.00$0.00
Other Income/Expenses (Net)$10.39M$11.71M-$7.97M$8.15M
Income Before Tax-$84.42M-$74.59M-$84.31M-$57.00M
Income Before Tax Ratio$0.00$0.00$0.00$0.00
Income Tax Expense$157000.00$171000.00$40000.00$170000.00
Net Income-$84.58M-$74.76M-$84.34M-$57.17M
Net Income Ratio$0.00$0.00$0.00$0.00
EPS-$1.18-$1.05-$1.28-$0.88
Diluted EPS-$1.18-$1.05-$1.28-$0.88
Weighted Avg Shares Outstanding$71.61M$71.16M$65.68M$64.61M
Weighted Avg Shares Outstanding (Diluted)$71.61M$71.16M$65.68M$64.61M

The company's financials show resilient growth, with revenue advancing from $0.00 in Q2 2024 to $0.00 in Q1 2025. Gross profit remained healthy with margins at N/A in Q1 2025 compared to N/A in Q2 2024. Operating income hit -$94.81M last quarter, sustaining a consistent N/A margin. Changes in R&D and SG&A spending did not hinder EBITDA, which stood at -$94.81M. Net income dropped to -$84.58M, while earnings per share reached -$1.18. Strong cost management and operational efficiency kept profitability intact, underlining the company's stable and competitive market performance.

Unlock 25+ Years of Financial Data

Get access to extended historical data, advanced metrics, and more with our premium plan

Frequently Asked Questions

;